beigen could excercis option higher pt reiter buy
provid corpor updat leap report revenu
net loss per share compar consensu revenu
consensu loss per share updat
model base report financi result project
revenu net loss per share end leap
cash cash equival believ
suffici fund oper
combin studi beigen could initi
januari leap announc compani enter
exclus option licens agreement beigen bgne
rate develop commerci
asia exclud japan australia new zealand part
collabor leap plan evalu combin
beigen antibodi tislelizumab approxim
patient second-lin gastroesophag junction cancer gej
gastric cancer gc tumor approxim
patient first-lin gc gej manag expect initi
phase studi expect data readout studi
anticip beigen exercis option develop
commerci pend posit result studi
posit data combin pembrolizumab
bode well phase studi recal leap present final
data phase clinic studi combin
pembrolizumab market merck rate keytruda
gej gc patient annual gastrointestin cancer
symposium american societi clinic oncolog held
patient previous treat
therapi patient experienc
week median progression-fre surviv mpf nearli week
median overal surviv mo orr dcr
believ result bode well plan studi evalu
combin beigen antibodi tiselizumab
chang financi model light leap plan initi
phase studi evalu combin beigen
tizelizumab includ revenu associ program
financi model expect beigen exercis option
anticip launch beigen commerci territori
result chang expect leap gener
risk-adjust revenu previous
furthermor expect decreas project expens
onward beigen expect respons larg
portion develop accordingli rais
price target per share previou
definit distribut analyst rate analyst certif disclosur pleas refer page report
valuat maintain buy rate lptx adjust price target per share
deriv price target base risk-adjust npv rnpv analysi project revenu assum
discount rate termin growth rate deriv rnpv product add cash cash
equival arriv price target per dilut share round
risk clinic commerci partnership financi legal intellectu properti impact
sale
research develop expens
gener administr expens
australian research develop incent
loss incom tax provis
accret prefer stock redempt valu
net incom loss attribut common
chang fair valu warrant liabil
compani report wainwright estim
sale
research develop expens
gener administr expens
australian research develop incent
loss incom tax provis
accret prefer stock redempt valu
net incom loss attribut common stockhold
chang fair valu warrant liabil
compani report wainwright estim
cash equival
research develop incent receiv
prepaid expens current asset
properti equip net
research develop incent receiv net current portion
note payabl accru interest-rel parti
accumul comprehens incom loss
total liabil stockhold equiti
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori leap inc lptx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
swayampakula ramakanth ph sean sean kang arthur ph certifi view express
report accur reflect person view subject secur issuer discuss part
compens directli indirectli relat specif recommend view express
research report neither member household offic director advisori board member
compani
none research analyst research analyst household financi interest secur leap
inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
leap inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens leap inc non-invest bank servic previou
firm affili receiv compens leap inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market leap inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
